Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 19, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation

CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new...
October 01, 2021 08:44 ET | Source: Beam Therapeutics

Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
September 28, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
September 27, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...
September 23, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new...
September 08, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
August 10, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results

Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE,...
August 03, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
July 08, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
May 25, 2021 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right